Biopsies during prostate cancer treatment to study resistance
Part of Cancer, Kidney & urinary clinical trials.
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed prostate cancer based on biopsy/pathology results
- You are able to receive 177Lu-PSMA therapy through an approved study or expanded access program
- Your scans (PET/CT) show a lymph node or soft-tissue area that can be safely biopsied
- Your blood counts are adequate for a biopsy (platelets above 75,000) within the last 14 days
- Your blood clotting tests (PT/INR and PTT) are not too abnormal within the last 14 days
- If you take blood thinners (like warfarin, aspirin, or other anti-coagulants), you can safely stop them for one week before the biopsy (your team must approve this)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This study looks at tissue samples from tumors to understand how and why PSMA radioligand therapy may become less effective. If you have PSMA-avid cancer lesions that can be biopsied, the trial may help researchers find ways to improve treatment.
This study tests a new way to guide prostate biopsies using a special scan (PSMA PET/CT) that highlights suspicious areas. If you need a biopsy because of high PSA and abnormal MRI, this approach might help make the biopsy more accurate.
Hear when a new Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.